The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia

Ibrutinib, the first in class of the oral covalent Bruton tyrosine kinase (BTK) inhibitors, has profoundly changed the treatment landscape of chronic lymphocytic leukemia (CLL). The phase III RESONATE and RESONATE-2 trials first demonstrated the superiority of ibrutinib over ofatumumab in the relaps...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Max J., Danilov, Alexey V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Evolving Landscape in Chronic Lymphocytic Leukemia Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970705/
https://www.ncbi.nlm.nih.gov/pubmed/33796237
http://dx.doi.org/10.1177/2040620721989588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970705/
https://www.ncbi.nlm.nih.gov/pubmed/33796237
http://dx.doi.org/10.1177/2040620721989588

Ejemplares similares